Core Insights - On September 18, Hanbang Technology experienced a decline of 1.69% with a trading volume of 53.52 million yuan [1] - The company had a net financing buy of -0.94 million yuan on the same day, with a total financing and securities balance of 92.89 million yuan [1] Financing Overview - On September 18, Hanbang Technology had a financing buy of 10.95 million yuan, with a current financing balance of 92.89 million yuan, accounting for 12.21% of the circulating market value [1] - There were no shares repaid or sold in the securities lending market on that day, resulting in a securities lending balance of 0.00 yuan [1] Company Profile - Hanbang Technology, established on October 28, 1998, is located in Huai'an Economic and Technological Development Zone, Jiangsu Province [1] - The company specializes in providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1] - The revenue composition includes: 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1] Financial Performance - As of June 30, the number of shareholders for Hanbang Technology was 9,372, a decrease of 48.43% from the previous period [2] - The average circulating shares per person increased by 93.92% to 1,764 shares [2] - For the first half of 2025, the company reported a revenue of 349 million yuan, a year-on-year increase of 5.99%, while the net profit attributable to the parent company was 27.80 million yuan, a decrease of 26.24% year-on-year [2] - As of June 30, the largest circulating shareholder was Dongfanghong Medical Upgrade Stock Initiation A (015052), holding 483,700 shares as a new shareholder [2]
汉邦科技9月18日获融资买入1094.57万元，融资余额9288.93万元